Shares of Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 429,810 shares traded hands during trading, an increase of 3,045% from the previous session's volume of 13,666 shares.The stock last traded at $5.07 and had previously closed at $5.02.
Hypermarcas Stock Performance
The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.63. The stock's 50-day moving average price is $4.10 and its 200-day moving average price is $3.52. The company has a market capitalization of $3.13 billion, a P/E ratio of 20.60 and a beta of 0.79.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter. Hypermarcas had a net margin of 12.51% and a return on equity of 6.95%. The company had revenue of $184.34 million for the quarter.
Hypermarcas Company Profile
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
